Corbus Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:CRBP)

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) saw some unusual options trading activity on Monday. Stock investors purchased 7,228 call options on the company. This is an increase of 523% compared to the typical volume of 1,160 call options.

Corbus Pharmaceuticals Trading Down 0.5%

Corbus Pharmaceuticals stock opened at $8.08 on Tuesday. Corbus Pharmaceuticals has a 12 month low of $7.12 and a 12 month high of $20.56. The stock has a fifty day simple moving average of $9.75 and a two-hundred day simple moving average of $9.45. The firm has a market cap of $150.85 million, a price-to-earnings ratio of -1.31 and a beta of 2.63.

Corbus Pharmaceuticals (NASDAQ:CRBP) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.55). On average, equities research analysts forecast that Corbus Pharmaceuticals will post -5.62 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on CRBP shares. HC Wainwright reiterated a “buy” rating and set a $35.00 price objective on shares of Corbus Pharmaceuticals in a research note on Monday. Oppenheimer cut their target price on Corbus Pharmaceuticals from $52.00 to $48.00 and set an “outperform” rating on the stock in a research note on Friday, August 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a report on Friday, July 17th. Mizuho set a $33.00 price target on Corbus Pharmaceuticals in a research report on Thursday, August 13th. Finally, Guggenheim reiterated a “buy” rating on shares of Corbus Pharmaceuticals in a research note on Tuesday, May 26th. Eight analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $41.00.

Insider Buying and Selling

In other news, CFO Sean F. Moran sold 12,000 shares of Corbus Pharmaceuticals stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $10.08, for a total transaction of $120,960.00. Following the completion of the transaction, the chief financial officer directly owned 84,694 shares in the company, valued at approximately $853,715.52. This trade represents a 12.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Nishant C. Saxena purchased 2,600 shares of the company’s stock in a transaction dated Tuesday, August 11th. The stock was bought at an average cost of $9.63 per share, for a total transaction of $25,038.00. Following the completion of the transaction, the insider owned 77,900 shares in the company, valued at approximately $750,177. This represents a 3.45% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 3.50% of the stock is currently owned by insiders.

Institutional Trading of Corbus Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Orbimed Advisors LLC raised its holdings in shares of Corbus Pharmaceuticals by 8.8% during the first quarter. Orbimed Advisors LLC now owns 1,737,287 shares of the biopharmaceutical company’s stock valued at $16,313,000 after purchasing an additional 140,000 shares during the last quarter. Exome Asset Management LLC boosted its holdings in Corbus Pharmaceuticals by 67.8% in the first quarter. Exome Asset Management LLC now owns 234,136 shares of the biopharmaceutical company’s stock worth $2,199,000 after purchasing an additional 94,593 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Corbus Pharmaceuticals by 76.6% in the first quarter. Dimensional Fund Advisors LP now owns 136,602 shares of the biopharmaceutical company’s stock worth $1,281,000 after purchasing an additional 59,248 shares during the last quarter. Seven Fleet Capital Management LP grew its position in Corbus Pharmaceuticals by 51.0% in the 1st quarter. Seven Fleet Capital Management LP now owns 85,687 shares of the biopharmaceutical company’s stock worth $805,000 after purchasing an additional 28,937 shares during the period. Finally, Bank of New York Mellon Corp bought a new stake in Corbus Pharmaceuticals in the 2nd quarter worth approximately $425,000. Hedge funds and other institutional investors own 64.64% of the company’s stock.

Trending Headlines about Corbus Pharmaceuticals

Here are the key news stories impacting Corbus Pharmaceuticals this week:

• Positive Sentiment: CRB-913 produced statistically significant and clinically meaningful average weight loss of approximately 5% at the 60 mg dose after 12 weeks in the CANYON-1 trial. No weight-loss plateau was observed, suggesting potential for additional benefit with longer treatment. Corbus Announces Positive Topline Data from CANYON-1 Study
• Positive Sentiment: The company said CRB-913 was generally well tolerated, with an emerging gastrointestinal tolerability profile and psychiatric adverse events broadly comparable with GLP-1 medicines. Reports also emphasized that the drug did not show the depressive effects that can concern investors in this therapeutic area. Corbus Obesity Drug Avoids Depressive Effects
• Positive Sentiment: The results support Corbus’s effort to develop a potentially differentiated, daily oral, non-incretin obesity treatment. The data were selected for a late-breaking presentation at ObesityWeek 2026, which could provide additional visibility. CRB-913 Phase 1b Topline Results Transcript
• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and maintained a $35 price target, implying substantial upside from the stock’s recently cited price of $8.08. Call-option purchases also surged to 7,228 contracts, versus average volume of 1,160, reflecting bullish speculative interest.
• Negative Sentiment: CRB-913 remains an early-stage program based on topline Phase 1b data. The candidate must demonstrate durability, safety, and competitive efficacy in larger, later-stage trials before it can generate revenue, leaving substantial clinical and financing risk.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.